News

Quickly consult our archives filtering by year :

Swiss Healthcare Licensing Group 2018 Winter Conference – another fantastic success!

Basel, 16th February 2018 – The Swiss HLG, a non-profit association of Business Development and Licensing professionals, held its 27th Conference titled “ Reset Partnering – Step out of the Box!” With partnering deals increasing in complexity, the evolution from pharmaceuticals to solutions and the consumerization of healthcare, Business Development, and Licensing professionals need to ask themselves if the tools and approaches used are still fit for purpose in the healthcare world of 2018.

Over three days, more than 100 delegates from Switzerland, Europe, the US and Asia gathered in the Swiss Alps to explore and exchange on the future of partnering and to take a step out of the Box.

Conference Director, Chris Isler with the active support of the entire Swiss HLG Board, convened a global panel of leading experts from the healthcare and consumer industry addressing three main questions:

  • How can we find the right deal for a specific question?
  • What is required to partner beyond the molecule?
  • Are there any new approaches we can learn from the consumer industry?

Before the start of the conference, Anthony A. Hörning, CEO of Strategic Transactions Advisor and former head of Alliance Management at Novartis led a dynamic and interactive workshop helping participants to understand “What happens after marriage – managing complex alliances”.

As an introduction, Jean-Paul Clozel, CEO of Idorsia and former CEO of Actelion, brilliantly set the stage with his thought-provoking keynote speech on his company has been acquired by Johnson & Johnson, despite not willing himself to sell it. He brought the audience to think on how the relationship and trust dimension were important to make such a transaction a success.

Francesco De Rubertis, CEO of the Medicxi Venture Fund expanded on Clozel’s thoughts with the view from the VC’s perspective and explained how entrepreneurialism and venture capital could go hand in hand. He shared his opinion as VC vs JP Clozel vision as an entrepreneur.

One of the Swiss HLG objectives is not just professional but also personal development, and hence Design Thinking Master, Rana Lonnen, Head Search and Evaluation Strategic Venture Capital at Novartis Pharma opened the day on Monday exploring how design thinking approaches can be leveraged in a partnering setting.

Six captivating presentations illustrated then what, along with the partnering process, is required to find the right deal. Alan Selby, Executive Director at Torreya Partners, shared his thoughts on when to use a broker or not. Emma Barton, Director Alliance, and Integration Management at AstraZeneca explained how Outlicensing can preserve the value of a molecule. Shigeo Taniuchi, Head of EMEA, Senior Corporate officer at Santen Pharmaceutical and Viren Mahurkar, formerly at Alcon took a look at the cultural dimension of partnerships and what to bear in mind when working with partners in Japan or China.

Tanja Dowe, CEO of the Debiopharm Innovation Fund focused on how to find the right deal with a VC fund and last but not least Vikalp Mohan, Vice President Sales and Marketing at Celonic took a look at how to partner with a Contract Development and Manufacturing Organization.

After a full day of presentations, the delegates enjoyed a short walk and typical Swiss Fondue Dinner in a barn and used the opportunity to expand their personal and professional networks.

The last day of the conference focused on how to partner beyond the molecules, starting with a case study looking at how to make more out of data by Dr. Alexandra V. Eberhard, Managing Director Europe, and Executive VP Sciences at Signals Analytics. Michael Meissner, Chief Technology Officer, at Sanofi took a look at how technology is becoming increasingly important for pharma and asked the question if pharma in this picture is the boiling frog. Ravi Sodha, Senior Director, Business Development at Actelion closed this block in sharing his perspectives on what makes deals for rare diseases different.

The closing keynote, delivered by Jon Otterstatter, CEO of the Preventice Solutions Group took the audience along the journey of building a highly successful medical technology start-up from scratch to a 500+ employee organization with prominent investors such as Merck Inc or Boston Scientific.

The Swiss HLG Board thanks the presenters and the participants for the lively discussion and interactions. Please find below some images from the conference. (Please click on the image to view it in its entirety and or a slide show.)

Read More…

Take a look at some impressions from our Winter Conference 2018.

Informative, exciting and a great opportunity to meet and exchange ideas with other Business Development Professionals.

https://www.flickr.com/photos/organizersgmbh/sets/72157691112123181/

 

We are excited to welcome you to our Winter Conference 2018!

We are thrilled to announce that we have more than 100 Business Development professionals attending our Winter Conference this year.

The next few days are the perfect opportunity to meet and build personal relationships with leading executives not only the from the healthcare industry, but our growing network from MedTech, Generics, Biosimilars, Investment & Finances, Biotech & Startup, Health Food Industry, Cosmetics and Legal & IP industries.

We look forward to the informative discussions about this year’s topic ” Reset Partnering- Step out of the Box!”

Swiss HLG and BaselArea are excited to invite you to the Swiss HLG’s 4th start-up workshop collaboration.

“Valuation of Early Stage Biotech Companies – Net Present Value versus VC approach.”

The risk-adjusted, net present value (rNPV) method is the standard valuation method used within pharma and biotech companies when valuing assets beyond discovery stage. This approach depicts the drug/pipeline development plan using R&D costs & timeline, success rates, and peak sales potential. The quantity of available information in the pharmaceutical area enables to determine and benchmark those assumptions. Well-calibrated the rNPV method is thus a powerful tool to build, challenge and value the company’s strategy. It also shows how the value of the company develops along reaching milestones. Is it however enough for investors?

From an investor’s perspective, it is crucial to understand how long it takes before an exit and what is the potential for ROI (Return on Investment). They need to figure out the conditions to harvest their investment as well as to anticipate the multiple later-round investors and incentive packages to key employees that may dilute their stake.

While rNPV highlights the roadmap for the scientific bet of the company, the VC method highlights the one for the cash to be invested in.

The purpose of this workshop is to decrypt the reasons behind using rNPV or VC methodologies to value a Biotech company. With the support of interactive cases, the participants will learn more about how Biotech companies can better anticipate the VCs’ point of view when presenting their valuation work.

Workshop Details:
Thursday, 8th February 2018
16:00
24 Gewerbestrasse, Swiss Innovation Parc-Allschwil

Participation is free of charge, but seats are limited.

To register,  email: stephan.emmerth@baselarea.swiss , please mention when registering that you are a  Swiss HLG member.

Registration is compulsory and subjected to validation. Priority is given to people with founded start-ups or concrete projects.

We look forward to meeting you there.

 

Join us, become a member !

Join Swiss HLG
as a member

Newsletter

Keep up to date with the latest information by signing up to our newsletter

Why it's worth joining us !

Learn more about Swiss HLG
and our initiatives